Single Nucleotide Polymorphism Genotyping Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Single Nucleotide Polymorphism Genotyping Market is projected to expand from USD 13.18 Billion in 2025 to USD 34.07 Billion by 2031, achieving a CAGR of 17.15%. Single Nucleotide Polymorphism genotyping is a specialized analytical method used to measure genetic variations at specific positions within DNA sequences to uncover markers associated with diseases or physiological traits. This market is primarily driven by the worldwide transition toward precision medicine and the integration of pharmacogenomics into clinical care, which requires precise genetic profiling for customized treatments. According to the Personalized Medicine Coalition, 18 new personalized medicines were FDA-approved in 2024, accounting for 38 percent of all newly authorized therapeutic molecular entities, highlighting the critical reliance on genotyping technologies for patient stratification and modern drug development.

Despite these positive growth indicators, the industry confronts significant obstacles regarding the management of sensitive biological data. A primary challenge that threatens to slow market progression is the rigorous regulatory environment governing genetic data privacy and security. The high costs and operational intricacies involved in adhering to shifting international data protection standards can erect entry barriers for smaller diagnostic laboratories and restrict the broader uptake of these services.

Market Drivers

Rising investments in genomic research and biobanking serve as a major driver for the Single Nucleotide Polymorphism genotyping market, supplying essential capital for extensive population studies. Governments and private organizations are allocating significant funds to biobanks to establish robust genetic databases, which are crucial for detecting disease markers and creating precision therapies. This financial influx directly facilitates the acquisition of genotyping arrays and sequencing platforms needed to analyze millions of biological samples. For instance, the UK Government announced in July 2024 that the UK Biobank secured £16 million to modernize its cloud infrastructure, ensuring the secure storage and analysis of its massive genomic dataset, while Illumina reported full-year 2023 revenue of $4.50 billion in February 2024, reflecting strong global demand for high-throughput genetic analysis tools.

Additionally, the growing application of SNP genotyping in agricultural biotechnology is broadening the market's reach beyond human healthcare. Agricultural scientists and breeders are increasingly employing genotyping for marker-assisted selection to boost crop yields, enhance disease resistance, and refine livestock traits, thereby tackling global food security issues. This shift is bolstered by substantial public sector funding designed to modernize agriculture through genomic advancements. According to the USDA National Institute of Food and Agriculture's December 2023 notification for the 2024 cycle, approximately $300 million was made available to fund research priorities such as plant health and animal breeding genetics, incentivizing the adoption of SNP-based screening in standard agricultural practices.

Market Challenges

A significant obstacle restricting the growth of the Global Single Nucleotide Polymorphism (SNP) Genotyping Market is the strict regulatory framework regarding genetic data privacy and security. Because SNP genotyping entails analyzing highly sensitive DNA sequences to detect physiological traits and disease markers, the industry must comply with a complicated network of international data protection regulations, such as HIPAA in the United States and the GDPR in Europe. These laws enforce rigorous standards for patient consent management, data encryption, and cross-border information exchanges. The associated high costs and operational complexity of maintaining compliance establish substantial barriers to entry, especially for research institutions and smaller diagnostic laboratories without the financial backing of large pharmaceutical companies, effectively limiting innovation and market competition.

This regulatory pressure directly impedes market expansion by compelling organizations to allocate significant resources toward legal and compliance infrastructures instead of research and development. The challenge of adhering to these requirements is felt throughout the sector; according to the International Association of Privacy Professionals, only 20 percent of privacy experts expressed full confidence in their organization's ability to remain compliant with evolving privacy laws in 2024. This uncertainty deters investment in new genotyping initiatives and retards the advancement of precision medicine, as companies remain cautious about scaling operations given the risks of reputational damage and severe legal penalties.

Market Trends

The market is increasingly shifting toward Next-Generation Sequencing (NGS) technologies, which are replacing traditional arrays by allowing for the simultaneous detection of both novel and known variants. This transition offers the detailed genomic resolution necessary for complex trait analysis and advanced precision medicine. The growing adoption of high-fidelity sequencing platforms supports this movement, enabling researchers to accurately genotype challenging genomic regions that earlier technologies failed to resolve. Recent hardware distributions highlight this technological evolution; according to Pacific Biosciences' February 2025 financial report, the company shipped 23 Revio sequencing systems during the fourth quarter of 2024, signaling strong demand for high-throughput genomic infrastructure.

Concurrently, the application of liquid biopsy for non-invasive SNP detection is transforming clinical diagnostics. By examining cell-free DNA from blood samples, this method enables the detection of disease-linked mutations without the need for invasive tissue biopsies, allowing for the ongoing monitoring of conditions like cancer. This capability has driven the widespread adoption of highly sensitive genotyping assays in routine patient care. The extent of this integration is reflected in service volumes; according to Natera's February 2025 financial results, the company processed approximately 792,800 tests in the fourth quarter of 2024, emphasizing the significant market expansion in non-invasive genetic screening applications.

Key Players Profiled in the Single Nucleotide Polymorphism Genotyping Market

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Douglas Scientific LLC
• Illumina Inc.
• Life Technologies Corp.
• Luminex Corp
• Promega Corporation
• Thermo Fischer Scientific Inc.
• Fluidigm Corporation

Report Scope

In this report, the Global Single Nucleotide Polymorphism Genotyping Market has been segmented into the following categories:

Single Nucleotide Polymorphism Genotyping Market, by Technology:

• TaqMan SNP Genotyping
• Massarray SNP Genotyping
• SNP GeneChip Arrays
• Others

Single Nucleotide Polymorphism Genotyping Market, by Application:

• Animal Genetics
• Plant Improvement
• Diagnostic Research
• Pharmaceuticals and Pharmacogenomics
• Agricultural Biotechnology
• Others

Single Nucleotide Polymorphism Genotyping Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Single Nucleotide Polymorphism Genotyping Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.